All In Biotech

Drug Trial Radar · NCT04572295

A Study of E7090 as Monotherapy and in Combination With Other Anticancer Agents in Participants With Estrogen Receptor Positive (ER+) and Human Epidermal Growth Receptor 2 Negative (HER2-) Recurrent/Metastatic Breast Cancer

An Open-label Phase 1b Study of E7090 Monotherapy and in Combination With Other Anticancer Agents in Subjects With ER+, HER2- Recurrent/Metastatic Breast Cancer

Last checked: Nov 19, 2026Latest source record: Jul 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

51

Actual

Start

Oct 9, 2020

Primary completion

Jun 18, 2026

Study completion Jun 18, 2026

Sponsor

Lead sponsor
Eisai Co., Ltd.Eisai
Sponsor type
Industry
First posted
Oct 1, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary purpose of this study is to evaluate the tolerability and safety of E7090 as monotherapy and in combination with other anticancer agents in participants with ER+, HER2- recurrent/metastatic breast cancer and to determine the recommended dose (RD) of E7090 in combination with other anticancer agents for subsequent phase studies.

Conditions

  • Breast Neoplasms

Interventions

  • E7090Drug

    E7090 oral tablet.

  • FulvestrantDrug

    Fulvestrant intramuscular injection.

  • ExemestaneDrug

    Exemestane oral tablet.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1: Recommended Dose (RD) of E7090 in Combination With Other Anticancer AgentsTime frame: Up to Cycle 1 (each cycle length = 28 days)
  2. Part 1: Number of Participants With Dose-limiting Toxicities (DLTs)Time frame: Up to Cycle 1 (each cycle length = 28 days)
  3. Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: Up to 30 days after last administration of study drug (approximately up to 66 months)

Locations

11 sites in 1 country. Site status is shown where the registry gives one.

  • Eisai Trial Site 11

    Nagoya, Aichi-ken, Japan

  • Eisai Trial Site 6

    Kashiwa, Chiba, Japan

  • Eisai Trial Site 9

    Matsuyama, Ehime, Japan

  • Eisai Trial Site 5

    Yokohama, Kanagawa, Japan

  • Eisai Trial Site 4

    Sendai, Miyagi, Japan

  • Eisai Trial Site 7

    Chuo-ku, Osaka, Japan

  • Eisai Trial Site 10

    Kitaadachi-gun, Saitama, Japan

  • Eisai Trial Site 3

    Chuo-ku, Tokyo, Japan

  • Eisai Trial Site 1

    Koto-ku, Tokyo, Japan

  • Eisai Trial Site 2

    Shinagawa-ku, Tokyo, Japan

  • Eisai Trial Site 8

    Shinjuku-ku, Tokyo, Japan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.